Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E7.85 EPS (ttm)9.21 Insider Own0.40% Shs Outstand1.31B Perf Week-0.50%
Market Cap94.86B Forward P/E9.50 EPS next Y7.61 Insider Trans-9.42% Shs Float1.30B Perf Month-0.52%
Income12.21B PEG- EPS next Q2.10 Inst Own76.90% Short Float1.30% Perf Quarter12.28%
Sales28.47B P/S3.33 EPS this Y-16.50% Inst Trans-0.11% Short Ratio1.91 Perf Half Y2.89%
Book/sh17.35 P/B4.17 EPS next Y-13.09% ROA21.10% Target Price79.68 Perf Year-10.36%
Cash/sh16.09 P/C4.50 EPS next 5Y-8.51% ROE61.90% 52W Range63.76 - 82.10 Perf YTD1.02%
Dividend2.08 P/FCF8.79 EPS past 5Y41.20% ROI31.00% 52W High-11.89% Beta1.24
Dividend %2.88% Quick Ratio3.20 Sales past 5Y29.40% Gross Margin84.90% 52W Low13.46% ATR1.08
Employees9000 Current Ratio3.40 Sales Q/Q-8.20% Oper. Margin57.80% RSI (14)49.57 Volatility1.06% 1.47%
OptionableYes Debt/Eq0.00 EPS Q/Q-9.60% Profit Margin42.90% Rel Volume1.02 Prev Close73.35
ShortableYes LT Debt/Eq1.16 EarningsJul 26 AMC Payout21.30% Avg Volume8.80M Price72.34
Recom2.50 SMA20-2.28% SMA502.23% SMA2002.85% Volume8,972,167 Change-1.38%
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $79
Mar-09-17Resumed UBS Neutral $118 → $72
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Sep-06-16Upgrade Jefferies Hold → Buy
Jul-29-16Downgrade Argus Buy → Hold
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Aug-17-17 07:35AM  3 Value Stocks for Retirees Motley Fool
05:59AM  Gilead Receives Approval in Canada for VOSEVI (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection CNW Group
Aug-16-17 08:47AM  Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL) Zacks
08:04AM  Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review Zacks
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Aug-15-17 04:22PM  Why Gilead Sciences Might Not Make an Oncology Acquisition Motley Fool
09:58AM  Zacks.com featured highlights: Coca-Cola FEMSA, Banco Bilbao Vizcaya Argentaria, Lantheus Holdings, Gilead Sciences and Lam Research Zacks
Aug-14-17 09:39PM  3 Healthcare Stocks That Are Looking Cheap Right Now Motley Fool
02:20PM  What Trump has done to lower the RIPOFF DRUG PRICES hes decrying Yahoo Finance
11:56AM  Zacks.com featured highlights: Broadcom Limited, CBRE Group, Sandvik AB, Applied Materials and Gilead Sciences Zacks
09:44AM  Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review Zacks
09:05AM  5 Discounted PEG Stocks for GARP Investors Zacks
Aug-13-17 02:03PM  Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions? Motley Fool
Aug-12-17 07:40PM  Edited Transcript of GILD earnings conference call or presentation 26-Jul-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 11:26PM  [$$] U.K. Health Service Turns to Clinical Trial to Make Cheaper HIV Drug Available The Wall Street Journal
05:57PM  [$$] England Turns to Clinical Trial to Get HIV Drug for Less The Wall Street Journal
01:25PM  Call of the week: Best stocks for a dollar bear market Yahoo Finance
01:13PM  Call of the week: best stocks for a dollar bear market Yahoo Finance Video
08:42AM  Forget Teva (TEVA), Buy These 4 Drug Stocks Instead Zacks
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
06:31AM  Markets Remain Choppy on Continuing Conflicts: 5 Top Picks Zacks
Aug-10-17 04:01PM  Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV Business Wire
10:52AM  Gilead Sciences: Easier Said Than Done Barrons.com
08:50AM  Major Biotechs Send Short Sellers Running for Cover 24/7 Wall St.
08:03AM  IHS Markit Score downgrades Gilead Sciences Inc to 64 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
07:00AM  These Managers Like Big Bets Morningstar
Aug-09-17 03:08PM  Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View Zacks
02:37PM  Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View Zacks
12:45PM  Third Point's Rumored Involvement Boosts Gilead Sciences Barrons.com
08:08AM  Biotech Breakouts Suggest It Is Time to Buy Investopedia
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Aug-08-17 09:00PM  Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher InvestorPlace
01:50PM  Mallinckrodt (MNK) Tops Q2 Earnings, Generics Segment Weak Zacks
09:25AM  Forget Bayer, Buy These 3 Drug Stocks Instead Zacks
Aug-07-17 09:31AM  These 3 Biotechs Just Crushed Analyst Expectations Motley Fool
09:15AM  Top Ranked Momentum Stocks to Buy for August 7th Zacks
08:00AM  AbbVie Wages HCV Drug-Price War on Gilead Bloomberg
Aug-06-17 10:37AM  AbbVies new, cheaper hepatitis C drug could launch the drug worlds own Hunger Games MarketWatch
08:21AM  10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year Motley Fool
Aug-05-17 06:45AM  Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance? Motley Fool
Aug-04-17 11:46PM  [$$] Another Price Squeeze for Drug Makers The Wall Street Journal
06:04PM  Analysts say a United Therapeutics sale is premature American City Business Journals
05:04PM  Celgene vs. Gilead Sciences: Who Reported Better Earnings? Motley Fool
04:29PM  Infinity (INFI) Q2 Loss Wider than Expected, View Intact Zacks
03:43PM  Radius (RDUS) Q2 Loss Wider than Expected on Higher Expenses Zacks
02:25PM  [$$] Another Price Squeeze for Drug Makers The Wall Street Journal
01:32PM  How AbbVie's 'Gauntlet' Could Squeeze Gilead's Drugs In Hepatitis C Investor's Business Daily
12:15PM  Gilead Could Be Making An Acquisition But It's Not What You Think Investor's Business Daily
10:39AM  Analysts Recommendations for AbbVie in August 2017 Market Realist
Aug-03-17 06:27PM  The FDA Just Approved the First Drug That Can Treat All Hepatitis C Strains in Just 8 Weeks Fortune
04:43PM  Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View Zacks
09:46AM  Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons InvestorPlace
Aug-02-17 10:10AM  Aerie (AERI) Reports Narrower-Than-Expected Loss in Q2 Zacks
08:32AM  Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote Zacks
07:37AM  HIV Drugs Are Expected to Boost Gilead Sciences Revenue Growth Market Realist
07:10AM  Featured Company News - Loxo Oncology Acquires Reversible BTK Inhibitor Program from UK Biotech Firm Redx Pharma ACCESSWIRE
Aug-01-17 04:01PM  U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV Business Wire
11:35AM  Biotech Stocks Seen Fueled by Next M&A Wave Investopedia
10:41AM  How Gilead Sciences HCV Franchise Is Positioned after 2Q17 Market Realist
09:20AM  August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty Benzinga
09:13AM  How Gilead Sciences Performed in 2Q17 Market Realist
07:43AM  Analysts Recommendations for Gilead Sciences in July 2017 Market Realist
12:26AM  3 ETFs to Watch Out for on Biotech Earnings Zacks
Jul-31-17 04:26PM  5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You Motley Fool
Jul-28-17 12:26PM  AbbVie to remain cautious on drug pricing, shares fall Reuters
08:54AM  4 Drug Stocks in Focus this World Hepatitis Day Zacks
07:00AM  Gilead's HCV and HIV Drugs Support Wide Moat Morningstar
05:46AM  European Commission Grants Marketing Authorization for Gileads Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C Business Wire
Jul-27-17 04:29PM  Biotech Fever Cools As These Players Dip On Longer-Term Views Investor's Business Daily
12:39PM  Biotechs Sell-Side Roundup: Cowens Take on Gilead Sciences, Inc. (GILD) and Celgene Corporation (CELG) SmarterAnalyst
10:07AM  Gilead Sciences, Inc. (GILD) Stock Has Tremendous Potential Even Post-Rally InvestorPlace
10:07AM  Gilead Sciences: The Biggest of Beats? Barrons.com
08:23AM  Early movers: CMCSA, TWTR, VZ, PG, LUV, DNKN & more CNBC
08:09AM  3 Stocks to Watch on Thursday: Buffalo Wild Wings (BWLD), Gilead Sciences, Inc. (GILD) and PayPal Holdings Inc (PYPL) InvestorPlace
08:06AM  J.P. Morgan Elevates Price Targets on Gilead Sciences, Inc. (GILD) and Vertex Pharmaceuticals Incorporated (VRTX) After Glowing 2Q Performance SmarterAnalyst
08:00AM  Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up Zacks
Jul-26-17 09:30PM  Gilead beats Street 2Q forecasts Associated Press
07:30PM  Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense Motley Fool
06:13PM  Gilead Sciences profit falls, but beats Wall Street estimates Reuters
06:06PM  Analysts Recommendations for Bristol-Myers Squibb in 2Q17 Market Realist
06:02PM  Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales Motley Fool
05:59PM  "Fast Money" final trades: GILD, UAL and more CNBC Videos
05:50PM  Gilead Still Doesn't Get a Deal Pass Bloomberg
05:22PM  Gilead (GILD) Shares Pop on Q2 Earnings and Revenue Beats Zacks
05:06PM  After-hours buzz: FB, PYPL, BWLD & more CNBC
05:00PM  Gilead's Hepatitis C Franchise Topples Again, But Shares Up On Beat Investor's Business Daily
05:00PM  Gilead surges after hours CNBC Videos
04:26PM  Gilead Sciences quarterly results beat Wall Street estimates Reuters
04:16PM  Gilead Sciences shares rise after quarterly results top Street view MarketWatch
04:04PM  Gilead Sciences beats the Street CNBC Videos
04:02PM  Gilead Sciences Announces Third Quarter 2017 Dividend Business Wire
04:01PM  Gilead Sciences Announces Second Quarter 2017 Financial Results Business Wire
09:35AM  Short Sellers Run for Cover From Major Biotech Stocks 24/7 Wall St.
09:35AM  Investor Network: Gilead Sciences, Inc. to Host Earnings Call Accesswire
06:00AM  Gilead Faces 6th Quarter of Falling Revenue Investopedia
Jul-25-17 05:30PM  Biotech still has more room to run: Technician CNBC Videos
02:31PM  What To Look For In Gilead Sciences, Inc. (GILD) Earnings SmarterAnalyst
11:18AM  Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK Zacks
08:30AM  Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season? Zacks
08:04AM  Gilead Sciences, Inc.s (GILD) Bictegravir Primed for Competition in HIV Market: Cowen SmarterAnalyst
Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., Galapagos NV., and Spring Bank Pharmaceuticals, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YOUNG KEVINChief Operating OfficerAug 10Option Exercise0.0091007,141Aug 14 06:57 PM
Meyers James REVP Worldwide Commercial OpsAug 10Option Exercise0.0082003,535Aug 14 06:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise21.5873,3331,582,1593,199,969Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Option Exercise26.998,625232,789106,113Aug 03 06:58 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale75.8673,3335,562,7773,126,636Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Sale75.8815,0001,138,19091,113Aug 03 06:58 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Option Exercise26.9934,500931,155137,488Jul 25 06:53 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Sale74.0040,0002,960,00097,488Jul 25 06:53 PM
MARTIN JOHN CExecutive ChairmanJul 03Option Exercise21.5873,3331,582,1593,199,969Jul 06 06:38 PM
MARTIN JOHN CExecutive ChairmanJul 03Sale71.0073,3335,206,8923,126,636Jul 06 06:38 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 03Sale71.065,000355,295102,988Jul 06 06:27 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise21.5873,3331,582,1593,273,302Jun 05 06:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJun 01Sale65.025,000325,114107,988Jun 05 06:15 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale65.2473,3334,784,5313,199,969Jun 05 06:26 PM
Cogan John FrancisDirectorMay 09Option Exercise20.7115,000310,57562,562May 11 06:14 PM
Cogan John FrancisDirectorMay 09Sale67.259,943668,66752,619May 11 06:14 PM
MARTIN JOHN CExecutive ChairmanMay 01Option Exercise21.5873,3331,582,1593,199,969May 03 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMay 01Sale68.315,000341,529112,988May 03 05:41 PM
MARTIN JOHN CExecutive ChairmanMay 01Sale68.3173,3335,009,4293,126,636May 03 05:42 PM
MARTIN JOHN CExecutive ChairmanApr 03Option Exercise21.5873,3331,582,1593,199,969Apr 05 05:29 PM
MARTIN JOHN CExecutive ChairmanApr 03Sale67.1873,3334,926,2873,126,636Apr 05 05:29 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMar 30Sale67.485,000337,392117,988Apr 03 06:23 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00173012,055Mar 03 06:03 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise21.5873,3331,582,1593,199,969Mar 03 06:29 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale70.3873,3335,161,2063,126,636Mar 03 06:29 PM
WILSON GAYLE EDirectorFeb 23Option Exercise20.7133,350690,512140,836Feb 27 06:29 PM
MILLIGAN JOHN FPresident and CEOFeb 23Option Exercise21.58100,0002,157,5001,165,924Feb 27 06:13 PM
WILSON GAYLE EDirectorFeb 23Sale69.3020,3651,411,374120,471Feb 27 06:29 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.0090802,883Feb 14 12:53 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise21.5873,3331,582,1593,204,429Feb 03 05:25 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.0062002,190Feb 03 05:32 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale72.5773,3335,322,0693,131,096Feb 03 05:25 PM
MARTIN JOHN CExecutive ChairmanJan 03Option Exercise21.5873,3371,582,2463,204,433Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanJan 03Sale73.5973,3375,396,9713,131,096Jan 05 03:39 PM
WILSON GAYLE EDirectorDec 01Option Exercise0.002,1470107,486Dec 05 07:59 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise16.40100,0001,639,5003,231,096Dec 05 12:54 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale73.33100,0007,332,8703,131,096Dec 05 12:54 PM
MADIGAN JOHN WDirectorNov 18Option Exercise20.71105,0002,174,025121,761Nov 22 02:45 PM
MADIGAN JOHN WDirectorNov 18Sale74.86105,0007,860,05916,761Nov 22 02:45 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 09Sale79.0010,000790,000122,964Nov 14 01:03 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise16.40100,0001,639,5003,231,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale73.76100,0007,376,0463,131,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanOct 03Option Exercise16.40100,0001,639,5003,231,096Oct 05 12:52 PM
MARTIN JOHN CExecutive ChairmanOct 03Sale77.63100,0007,762,9613,131,096Oct 05 12:52 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 22Sale81.845,000409,220132,964Sep 26 04:54 PM
MILLIGAN JOHN FPresident and CEOSep 06Option Exercise20.7470,0001,451,8001,128,963Sep 08 01:35 PM
MILLIGAN JOHN FPresident and CEOSep 06Sale77.7470,0005,442,0801,058,963Sep 08 01:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise16.40100,0001,639,5003,231,096Sep 06 02:40 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale77.48100,0007,748,3633,131,096Sep 06 02:40 PM
Lofton Kevin EDirectorAug 24Sale81.973,500286,8990Aug 25 05:05 PM